Table 2 Logistic regression demonstrates the correlation between PHGDH expression and clinicopathological features
Characteristics | Total(N) | Odds Ratio(OR) | P value |
|---|---|---|---|
Clinical stage (Stage II-IV vs. Stage I) | 552 | 1.448 (1.026–2.048) | 0.036* |
Primary therapy outcome (CR vs. PD&SD&PR) | 480 | 0.433 (0.206–0.862) | 0.021* |
Age (> 60 vs. <=60) | 549 | 1.251 (0.885–1.770) | 0.205 |
Weight (> 80 vs. <=80) | 528 | 0.773 (0.548–1.089) | 0.142 |
BMI (> 30 vs. <=30) | 519 | 0.891 (0.628–1.265) | 0.519 |
Histological type (Serous vs. Endometrioid) | 528 | 2.716 (1.770–4.232) | < 0.001* |
Residual tumor (R1&R2 vs. R0) | 413 | 0.963 (0.492–1.886) | 0.913 |
Histologic grade (G2&G3 vs. G1) | 541 | 3.010 (1.888–4.912) | < 0.001* |
Tumor invasion(%) ( > = 50 vs. <50) | 474 | 1.287 (0.896–1.851) | 0.172 |
Menopause status (Peri&Post vs. Pre) | 506 | 1.100 (0.551–2.203) | 0.786 |
Diabetes (Yes vs. No) | 451 | 0.949 (0.626–1.436) | 0.803 |